Koike Kazuhiko, Moriya Kyoji
Department of Infectious Diseases, Internal Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
J Gastroenterol. 2005 Apr;40(4):329-36. doi: 10.1007/s00535-005-1586-z.
Although the target of hepatitis C virus (HCV) infection is the liver, it has become progressively more evident that HCV can induce diseases in numerous organs. Recently, much attention has been drawn to metabolic disorders in HCV infection. Initially, hepatic steatosis and disturbances in lipid metabolism were found to be characteristic of HCV infection, and, subsequently, a correlation was noted between HCV infection and diabetes. It is now evident that HCV, by itself, can induce insulin resistance by way of disturbing the intracellular signaling pathway of insulin by the function of HCV core protein. Insulin resistance, caused by HCV infection, evolves to type 2 diabetes when superimposed on a high-fat diet and obesity. The fact that HCV infection induces insulin resistance by the virus itself may influence the progression of chronic hepatitis and open up novel therapeutic approaches. When hepatitis C is compared with nonalcoholic steatohepatitis (NASH), there are a number of similarities and several differences. From the metabolic aspect, hepatitis C resembles NASH in numerous features, such as the presence of steatosis, serum dyslipidemia, and oxidative stress in the liver, suggesting that hepatitis C is a steatohepatitis. In contrast, there are noticeable differences between hepatitis C and NASH, in that HCV modulates cellular gene expression and intracellular signal transduction, including the activation of mitogen-activated protein (MAP) kinase and transcription factor activator protein (AP)-1, while such details have not been noted for NASH. This difference may explain the markedly higher incidence of HCC development in chronic hepatitis C compared with that in NASH. HCV infection needs to be viewed not only as a liver disease but also as a metabolic disease, and this viewpoint could open up a novel way to the molecular understanding of the pathogenesis of hepatitis C, as a virus-associated steatohepatitis (VASH).
尽管丙型肝炎病毒(HCV)感染的靶器官是肝脏,但越来越明显的是,HCV可在许多器官中引发疾病。最近,HCV感染中的代谢紊乱受到了广泛关注。最初,肝脂肪变性和脂质代谢紊乱被发现是HCV感染的特征,随后,人们注意到HCV感染与糖尿病之间存在关联。现在很明显,HCV本身可通过其核心蛋白的功能干扰胰岛素的细胞内信号通路来诱导胰岛素抵抗。由HCV感染引起的胰岛素抵抗,在叠加高脂肪饮食和肥胖时会发展为2型糖尿病。HCV感染本身诱导胰岛素抵抗这一事实可能会影响慢性肝炎的进展,并开辟新的治疗方法。当将丙型肝炎与非酒精性脂肪性肝炎(NASH)进行比较时,存在许多相似之处和一些差异。从代谢方面来看,丙型肝炎在许多特征上与NASH相似,例如存在脂肪变性、血清血脂异常和肝脏中的氧化应激,这表明丙型肝炎是一种脂肪性肝炎。相比之下,丙型肝炎和NASH之间存在明显差异,因为HCV可调节细胞基因表达和细胞内信号转导,包括丝裂原活化蛋白(MAP)激酶和转录因子激活蛋白(AP)-1的激活,而NASH尚未发现此类细节。这种差异可能解释了慢性丙型肝炎中肝癌发生的发生率明显高于NASH。HCV感染不仅应被视为一种肝脏疾病,还应被视为一种代谢疾病,这种观点可能会为从分子层面理解丙型肝炎作为一种病毒相关性脂肪性肝炎(VASH)的发病机制开辟一条新途径。